EDP Sciences logo
Subscriber Authentication Point
Search
Menu
Home All issues Volume 35 / No 12 (Décembre 2019) Med Sci (Paris), 35 12 (2019) 1092-1097 References
Open Access
Issue
Med Sci (Paris)
Volume 35, Number 12, Décembre 2019
Anticorps monoclonaux en thérapeutique
Page(s) 1092 - 1097
Section Les nouveaux formats d’anticorps
DOI https://doi.org/10.1051/medsci/2019217
Published online 06 January 2020
  1. Ward ES, Güssow D, Griffiths AD, et al. Binding activities of a repertoire of single immunoglobulin variable domains secreted from Escherichia coli. Nature 1989 ; 341: 544–546. [Google Scholar]
  2. Hamers-Casterman C, Atarhouch T, Muyldermans S, et al. Naturally occurring antibodies devoid of light chains. Nature 1993 ; 363: 446–448. [Google Scholar]
  3. Dumoulin M, Conrath K, Van Meirhaeghe A, et al. Single-domain antibody fragments with high conformational stability. Protein Sci. Publ. Protein Soc 2002 ; 11: 500–515. [CrossRef] [Google Scholar]
  4. Greenberg AS, Avila D, Hughes M, et al. A new antigen receptor gene family that undergoes rearrangement and extensive somatic diversification in sharks. Nature 1995 ; 374: 168–173. [Google Scholar]
  5. Oliveira S, van Dongen GAMS, Stigter-van Walsum M, et al. Rapid visualization of human tumor xenografts through optical imaging with a near-infrared fluorescent anti-epidermal growth factor receptor nanobody. Mol Imaging 2012 ; 11: 33–46. [CrossRef] [PubMed] [Google Scholar]
  6. Weis W, Brown JH, Cusack S, et al. Structure of the influenza virus haemagglutinin complexed with its receptor, sialic acid. Nature 1988 ; 333: 426–431. [Google Scholar]
  7. Stijlemans B, Conrath K, Cortez-Retamozo V, et al. Efficient targeting of conserved cryptic epitopes of infectious agents by single domain antibodies. African trypanosomes as paradigm. J Biol Chem 2004 ; 279: 1256–1261. [CrossRef] [PubMed] [Google Scholar]
  8. Jemmerson R.. Multiple overlapping epitopes in the three antigenic regions of horse cytochrome c1. J Immunol 1987 ; 138: 213–219. [PubMed] [Google Scholar]
  9. Newman MA, Mainhart CR, Mallett CP, et al. Patterns of antibody specificity during the BALB/c immune response to hen eggwhite lysozyme. J Immunol 1992 ; 149: 3260–3272. [PubMed] [Google Scholar]
  10. Robin G, Sato Y, Desplancq D, et al. Restricted diversity of antigen binding residues of antibodies revealed by computational alanine scanning of 227 antibody-antigen complexes. J Mol Biol 2014 ; 426: 3729–3743. [Google Scholar]
  11. Weidle UH, Auer J, Brinkmann U, et al. The emerging role of new protein scaffold-based agents for treatment of cancer. Cancer Genomics Proteomics 2013 ; 10: 155–168. [PubMed] [Google Scholar]
  12. Yu X, Yang YP, Dikici E, et al. Beyond antibodies as binding partners: The role of antibody mimetics in bioanalysis. Annu Rev Anal Chem Palo Alto Calif 2017 ; 10: 293–320. [CrossRef] [Google Scholar]
  13. Vazquez-Lombardi R, Phan TG, Zimmermann C, et al. Challenges and opportunities for non-antibody scaffold drugs. Drug Discov Today 2015 ; 20: 1271–1283. [CrossRef] [PubMed] [Google Scholar]
  14. Hanes J, Schaffitzel C, Knappik A, et al. Picomolar affinity antibodies from a fully synthetic naive library selected and evolved by ribosome display. Nat Biotechnol 2000 ; 18: 1287–1292. [CrossRef] [PubMed] [Google Scholar]
  15. Orcutt KD, Adams GP, Wu AM, et al. Molecular simulation of receptor occupancy and tumor penetration of an antibody and smaller scaffolds: application to molecular imaging. Mol Imaging Biol 2017 ; 19: 656–664. [Google Scholar]
  16. Goux M, Becker G, Gorré H, et al. Nanofitin as a new molecular-imaging agent for the diagnosis of epidermal growth factor receptor over-expressing tumors. Bioconjug Chem 2017 ; 28: 2361–2371. [CrossRef] [PubMed] [Google Scholar]
  17. Schmidt MM, Wittrup KD. A modeling analysis of the effects of molecular size and binding affinity on tumor targeting. Mol Cancer Ther 2009 ; 8: 2861–2871. [CrossRef] [PubMed] [Google Scholar]
  18. Wittrup KD, Thurber GM, Schmidt MM, et al. Practical theoretic guidance for the design of tumor-targeting agents. Methods Enzymol 2012 ; 503: 255–268. [CrossRef] [PubMed] [Google Scholar]
  19. Nelson AL, Reichert JM. Development trends for therapeutic antibody fragments. Nat Biotechnol 2009 ; 27: 331–337. [CrossRef] [PubMed] [Google Scholar]
  20. Henricks LM, Schellens JHM, Huitema ADR, et al. The use of combinations of monoclonal antibodies in clinical oncology. Cancer Treat Rev 2015 ; 41: 859–867. [CrossRef] [PubMed] [Google Scholar]
  21. Klupsch K, Baeriswyl V, Scholz R, et al. COVA4231, a potent CD3/CD33 bispecific FynomAb with IgG-like pharmacokinetics for the treatment of acute myeloid leukemia. Leukemia 2019 ; 33: 3 805–808. [CrossRef] [PubMed] [Google Scholar]

Current usage metrics show cumulative count of Article Views (full-text article views including HTML views, PDF and ePub downloads, according to the available data) and Abstracts Views on Vision4Press platform.

Data correspond to usage on the plateform after 2015. The current usage metrics is available 48-96 hours after online publication and is updated daily on week days.

Initial download of the metrics may take a while.